Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Hussain, Sahil; Mursal, Mohd; Verma, Garima; Hasan, Syed Misbahul; Khan, Mohemmed Faraz

doi:10.1016/j.ejphar.2024.176484

European Journal of Pharmacology

2024

DOI: 10.1016/j.ejphar.2024.176484

|View full text |Cite

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Sahil Hussain,

Mohd Mursal,

Garima Verma

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 176 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Layer-by-layer fabrication of covalent organic frameworks on stainless steel needles as solid-phase microextraction probe coupled with electrospray ionization mass spectrometry for enrichment and determination of tyrosine kinase inhibitors in biosamples

Li,

Shi,

et al. 2024

Journal of Chromatography A

View full text Add to dashboard Cite

Layer-by-layer fabrication of covalent organic frameworks on stainless steel needles as solid-phase microextraction probe coupled with electrospray ionization mass spectrometry for enrichment and determination of tyrosine kinase inhibitors in biosamples

Li,

Shi,

et al. 2024

Journal of Chromatography A

View full text Add to dashboard Cite

Emerging Techniques in Cancer Therapy: Precision Targeting for Improved Outcomes

Kargbo

2024

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

The continuous evolution of cancer therapy has driven the exploration of novel strategies to improve treatment specificity and efficacy while minimizing adverse effects. This article examines two innovative approaches that offer new directions in targeting cancer cells. The first approach focuses on developing antibodies that specifically bind to peptide/major histocompatibility complex (MHC) complexes, enhancing the precision and effectiveness of immunotherapy. The second approach introduces quinazoline compounds that target and inhibit critical tyrosine kinases in cancer progression. Together, these advancements represent promising strides in the quest to develop more effective and precise cancer therapies, offering promising new avenues for treating resistant and aggressive forms of cancer. ImportantCompound Classes. Titles. Quinazoline Compound for Inducing Degradation of G12D-Mutation KRAS Protein; Compositions and Methods Comprising Antibodies that Bind Covalent Peptide Conjugates. Patent Publication Numbers. EP 4293024 A1 (URL: https://patents.google.com/patent/EP4293024A1/en?oq= EP+4293024+A1)WO 2023/250391 A2 (URL: https://patents.google.com/ p a t e n t / W O 2 0 2 3 2 5 0 3 9 1 A 2 / e n ? o q = WO+2023%2f250391+A2).

show abstract

Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases

Sabnis

2024

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Cited by 6 publications

References 176 publications

Layer-by-layer fabrication of covalent organic frameworks on stainless steel needles as solid-phase microextraction probe coupled with electrospray ionization mass spectrometry for enrichment and determination of tyrosine kinase inhibitors in biosamples

Layer-by-layer fabrication of covalent organic frameworks on stainless steel needles as solid-phase microextraction probe coupled with electrospray ionization mass spectrometry for enrichment and determination of tyrosine kinase inhibitors in biosamples

Emerging Techniques in Cancer Therapy: Precision Targeting for Improved Outcomes

Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases

Contact Info

Product

Resources

About